INVO Bioscience, Inc. (INVO) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 17, 2024, by INVO Bioscience, Inc. (the "Company"), a Nevada corporation. The report details two material events occurring in mid-April 2024: the termination of a material lease agreement for a proposed Tampa facility and a notice from Nasdaq regarding non-compliance with listing standards.
Key Financial Metrics and Liquidity
- Stockholders' Equity: Reported at $892,825 as of December 31, 2023 (per Form 10-K).
- Lease Assignment Proceeds: The Company received $475,000 from Brown Fertility Associates PA for the assignment of its Tampa lease.
- Use of Proceeds: $356,546.66 was utilized to settle buildout costs and accrued rent with the landlord. The remaining balance is designated for general working capital.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the current period.
Material Changes and Events
- Termination of Material Definitive Agreement (Item 1.02): On April 19, 2024, the Company assigned its lease for the Tampa INVO Center to Brown Fertility. This decision was driven by the unavailability of the proposed doctor and a strategic shift to prioritize the acquisition of profitable US-based fertility clinics.
- Nasdaq Delisting Notice (Item 3.01): The Company received notice from Nasdaq that it failed to meet Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. This follows a previous compliance period monitored by a Nasdaq Hearings Panel.
Outlook, Risks, and Management Commentary
- Strategic Pivot: Management is refocusing efforts on acquiring existing profitable clinics rather than building new centers, as evidenced by the Tampa lease assignment.
- Delisting Risk: The Company intends to appeal the Nasdaq determination by April 24, 2024, to avoid suspension of trading on April 26, 2024. Management is evaluating courses of action to regain compliance but noted there is no assurance that a plan will be accepted or that compliance will be achieved.
- Contingencies: If the appeal fails or compliance is not restored, the Company faces potential delisting from The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the status of the Company's appeal to the Nasdaq Hearings Panel and the outcome of the April 24, 2024 deadline.
- Confirm the specific plan submitted to Nasdaq to regain the $2.5 million stockholders' equity requirement.
- Review the Company's pipeline for acquiring profitable US-based fertility clinics to assess the viability of the new strategic direction.
- Monitor subsequent filings for updates on the Tampa lease settlement and the utilization of remaining working capital proceeds.